🔴 Problem Identified
European venture capital has shifted from funding high-risk, innovative startups to favoring safer, predictable investments resembling small-cap private equity. This “Safe Bet Syndrome” prioritizes revenue and proven teams over breakthrough technology and visionary founders, reducing the potential for outsized returns. As a result, there is a growing funding gap for transformational technologies emerging from academic research, while capital concentrates in low-risk SaaS ventures. This shift undermines the patient, risk-tolerant capital historically critical for major technological advances. To foster true innovation, Europe needs new investment institutions with long horizons willing to back high-risk, high-reward projects, bridging the gap between research and commercialization.
💡 Proposed Solution
Create a specialized investment platform and fund—"DeepTech Catalyst Fund"—that aggregates capital from institutions, family offices, and high-net-worth individuals seeking long-term, high-upside returns. The fund offers 15-20 year horizons, accepts high failure rates, and strategically partners with European universities to identify and co-develop promising spinouts. The platform also provides commercialization support services, including mentoring, regulatory navigation, and technical validati...
Register to read the full solution →
Market Size
Medium
Difficulty
High
Time to MVP
6+ months
Investment
High
Unlock Full Analysis
Get competitor analysis, cost breakdowns, implementation roadmaps, and AI-powered next steps.
Create Free AccountAlready have an account? Log in
Quick Overview
Target Audience
Academic spinouts, deep tech/startup founders, university tech transfer offices
Revenue Potential
€5M - €50M
Competition
Low
Key Advantage
First-mover in structured "patient capital" for deep tech, strong university partnerships, and commercialization experti...